micro-community-banner
  • Saved

3yr

SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature

Source : https://www.nmd-journal.com/article/S0960-8966(22)00650-2/fulltext

Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ). MG has an incidence of 30 per million/year in adults but is rarer (1-5 per million/year) in...


Relevance: Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered...

  • Saved

3yr
Neurological outcomes of extended thymectomy for thymomatous myasthenia gravis: Subxiphoid vs. trans-sternal approaches

Neurological outcomes of extended thymectomy for thymomatous myasthenia gravis: Subxiphoid vs. trans-sternal approaches

Source : https://www.frontiersin.org/articles/10.3389/fsurg.2022.973954/full

BackgroundThe subxiphoid approach has been widely used recently. However, there is little data focusing on neurological outcomes in patients with thymomatous myasthenia gravis (MG) who underwent subxiphoid thoracoscopic thymectomy.


Conclusions: In patients with Masaoka stage I and II thymoma who underwent thymectomy, with tumor size less than 5 cm and thymomatous MG, age ≦48 years and the subxiphoid approach were associated with a rapid improvement in clinical status.

  • Saved

3yr

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Source : https://jamanetwork.com/journals/jamaneurology/fullarticle/2796552


Meaning: Treatment with rituximab can be considered early after onset of generalized myasthenia gravis to reduce the risk of disease worsening and/or need of additional therapies.

  • Saved

3yr
Highlights from the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Neurologists, physical medicine and rehabilitation physicians, other allied health professionals, and researchers came together for the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) to learn from one another through plenary sessions and workshops that focused on the management and treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), muscular dystrophy, Duchenne muscular dystrophy, myasthenia gravis (MG), and spinal muscular atrophy. Click above for a summary of the last two days of the conference. We will follow this up with a post-conference wrap-up report soon.

  • Saved

3yr
Highlights from the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Neurologists, physical medicine and rehabilitation physicians, other allied health professionals, and researchers came together for the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) to learn from one another through plenary sessions and workshops that focused on the management and treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), muscular dystrophy, Duchenne muscular dystrophy, myasthenia gravis (MG), and spinal muscular atrophy. Click above for a summary of the last two days of the conference. We will follow this up with a post-conference wrap-up report soon.